SCHEMBL6038662

SCHEMBL6038662

COc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2OCc2ccncc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.57
LMNA P02545 1/20 0.57
HSD17B10 Q99714 1/20 0.57
MAPT P10636 5/20 0.56
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
RXFP1 Q9HBX9 1/20 0.50
ALDH1A1 P00352 3/20 0.49
HPGD P15428 1/20 0.49
POLB P06746 1/20 0.49
PIK3CD O00329 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PIK3CA P42336 1/20 0.47
PIK3CB P42338 1/20 0.47
PIK3CG P48736 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NAMPT P43490 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038498 0.90 MEN1 (0.61) KDM4ELMNAHSD17B10MAPTMEN1
SCHEMBL6039123 0.89 KDM4E (0.59) KDM4ELMNAHSD17B10MAPTMEN1
SCHEMBL6038689 0.89 KDM4E (0.67) KDM4ELMNAHSD17B10MAPTMEN1
SCHEMBL6038465 0.89 KDM4E (0.54) KDM4ELMNAHSD17B10MAPTMEN1
SCHEMBL6039230 0.88 KDM4E (0.61) KDM4ELMNAHSD17B10MAPTMEN1
SCHEMBL6038546 0.87 MEN1 (0.66) KDM4ELMNAHSD17B10MAPTMEN1
SCHEMBL6038921 0.87 KDM4E (0.56) KDM4ELMNAHSD17B10MAPTMEN1
SCHEMBL6038776 0.87 MEN1 (0.70) KDM4ELMNAHSD17B10MAPTMEN1
SCHEMBL6038487 0.86 LMNA (0.58) KDM4ELMNAHSD17B10MAPTMEN1
SCHEMBL6038817 0.86 MEN1 (0.57) KDM4ELMNAHSD17B10MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 KDM4E 3561/4885LMNA 4821/4885HSD17B10 2083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.